TCON TRACON Pharmaceuticals Inc.

2.60
-0.05  -2%
Previous Close 2.65
Open 2.65
Price To book 2.08
Market Cap 45531013
Shares 17,511,928
Volume 47,753
Short Ratio 1.86
Av. Daily Volume 142,694

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b enrollment to be completed 2018.
TRC105 + Avastin
Non-Squamous Cell Lung Cancer
Phase 1/2 dosing commenced May 24, 2017. Completion of dose escalation phase due 1H 2018.
TRC253
Prostate cancer
Phase 2 trial initiation announced July 25, 2017.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 dosing initiated May 2016 with data due 1H 2018.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 initiated Dec 2014. Completion of enrollment announced September 7, 2017. Top-line PFS data due early 2018.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 planned for 2016. Data due 2018.
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2018.
TRC102
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017. Interim analysis 2H 2018.
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 2 data due 2H 2017.
TRC105
Soft tissue sarcomas

Latest News

  1. TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget
  2. Edited Transcript of TCON earnings conference call or presentation 7-Nov-17 9:30pm GMT
  3. TRACON Pharmaceuticals Presents Updated Data from Phase 1b/2 Study of TRC105 and Votrient® in Patients with Soft Tissue Sarcoma Including Angiosarcoma
  4. Tracon beats 3Q profit forecasts
  5. TRACON Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
  6. TRACON Pharmaceuticals, Inc. to Host Earnings Call
  7. TRACON Pharmaceuticals to Present at Upcoming Investment Conferences
  8. TRACON to Report Third Quarter Company Highlights and Financial Results on November 7, 2017
  9. ETFs with exposure to TRACON Pharmaceuticals, Inc. : October 23, 2017
  10. TRACON Pharmaceuticals Announces Multiple TRC105 Poster Presentations at 18th IASLC World Conference on Lung Cancer
  11. TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
  12. TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma
  13. TRACON Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
  14. Edited Transcript of TCON earnings conference call or presentation 8-Aug-17 8:30pm GMT
  15. Tracon reports 2Q loss
  16. Investor Network: TRACON Pharmaceuticals, Inc. to Host Earnings Call

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171184461
  2. 8-K - Current report 171183735
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 171107862
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171067052
  5. CT ORDER - Confidential treatment order 171043737
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015792
  7. 8-K - Current report 171014699
  8. 8-K - Current report 17982885
  9. CT ORDER - Confidential treatment order 17928418
  10. 8-K - Current report 17914752